MediPines Corporation

MediPines Corporation develops the AGM100®, a non-invasive, point-of-care device for rapid assessment of cardiorespiratory function and pulmonary gas exchange. The AGM100 delivers oxygenation, ventilation, and gas exchange measurements in under 2 minutes with accuracy comparable to arterial blood gas analysis. Designed for emergency departments and acute care settings, it enables clinicians to quickly identify respiratory impairment severity and gas exchange abnormalities in patients presenting with dyspnea, chest pain, or undifferentiated respiratory distress. The device addresses critical diagnostic gaps in conditions such as COPD exacerbation, pneumonia, heart failure, pulmonary embolism, and acute asthma. FDA 510(k) cleared and newly reimbursable under dedicated CPT code, the AGM100 improves diagnostic efficiency, reduces unnecessary serial testing and observation admissions, and supports evidence-based treatment decisions at the point of care.